NT102 / Neuroene Therap - LARVOL DELTA

Neuroene Therapeutics Announces Orphan Drug Designation Granted by FDA for Dravet Syndrome Treatment - NT102 (PRNewswire) - "Neuroene Therapeutics announced that the FDA has granted orphan drug designation for the company's proprietary compound: NT102. NT102 was developed as part of a novel patented platform of mitochondrial and neuroprotective chemicals for the treatment of neurological diseases such as pharmacoresistant epilepsies."

Orphan drug • CNS Disorders • Epilepsy